Aptilon Announces Appointment of a New Director and Grant of Options
Robert H. Steinfeld, LL.M., J.D., served as Senior Vice President, General Counsel and Corporate Secretary of IMS Health Inc. from 2000 to 2009. He joined Cognizant Corporation in February, 1997 as Director of Taxes. He played a key role in the structuring of the IMS-Gartner Group spin-off and also in the Synavant spin-off. From
The Corporation's board of directors is now comprised of
Aptilon has also granted a total of 7,580,000 stock options, of which 6,200,000 were issued to directors and officers. Each option is valid for five years, is exercisable at a price of
Aptilon also announces that further to its acquisition of the assets of Direct Medical Data, LLC ("DMD") and BLM Incorporated announced on
About Aptilon Corporation -------------------------
Aptilon enables pharmaceutical, biotech and medical device companies to effectively reach and interact with physicians and healthcare professionals via the Internet through its innovative AxcelRx(SM) service, ReachNet(SM) healthcare professional access network and licensed access to over sixty professional databases. Top US pharmaceutical and healthcare companies have adopted Aptilon's solutions to improve their sales and marketing efforts to reach leading physicians and allied healthcare professionals on-line. Aptilon provides the necessary infrastructure for companies to build physician awareness, understanding, and product preference during all stages of a product's life cycle; from pre-launch education through end stage support. For more information, visit www.aptilon.com.
AxcelRx(SM) and ReachNet(SM) are service marks of Aptilon Corporation.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
%SEDAR: 00022191EFFor further information: Denis Martineau, President, Aptilon Corporation, 1-888-544-8866, firstname.lastname@example.org; Ross Marshall, Investor Relations, The Equicom Group, (416) 815-0700 x 238, email@example.com